Search Results - Application+%3e+Vaccines

206 Results

Sort By:

Human-Bovine Reassortant Rotavirus Vaccine

Rotavirus is a major cause of severe diarrhea and dehydration in infants and young children. Vaccines that cover the most important rotavirus serotypes could help reduce serious illness worldwide. Researchers at NIAID’s Laboratory of Infectious Diseases developed a multivalent human-bovine reassortant rotavirus vaccine using vaccine strains created...

Published: 5/28/2026 | Updated: 5/28/2026 | Inventor(s): Albert Kapikian (Estate Of), Robert Chanock (Estate), Yasutaka Hoshino

Keywords(s):

Category(s): TherapeuticArea, Application > Vaccines

A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions

The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent individuals could prevent a significant amount of human disease. The primary...

Published: 5/14/2026 | Updated: 5/14/2026 | Inventor(s): Patrick Duffy, Jonathan Renn

Keywords(s):

Category(s): Application, Application > Research Materials, Application > Therapeutics, Application > Vaccines, Collaboration Sought, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Sequences, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease

Neutralizing Antibodies Against West Nile Virus

West Nile virus (WNV) is a mosquito-borne virus that can cause severe disease affecting the brain and nervous system, especially in older adults and people with weakened immune systems. There is no approved human vaccine or specific antiviral treatment for WNV. Researchers at NIAID’s Vaccine Research Center (VRC), together with collaborators...

Published: 4/23/2026 | Updated: 4/22/2026 | Inventor(s): Theodore Pierson, Kimberly Dowd, Daniel Douek, Dror Harats, Yael Ottolenghi, Gili Regev-Yochay, Yaniv Lustig

Keywords(s):

Category(s): TherapeuticArea, Application > Vaccines, Application, Application > Diagnostics, ResearchProducts, ResearchProducts > Virus/Bacteria

Novel malaria vaccine candidates comprising engineered nanoparticles

Using proteins derived from the malaria Plasmodium falciparum parasite, NIAID has developed three different nanoparticle platforms to serve as scaffolds for displaying multiple copies of malaria antigens in an organized, repetitive manner to enhance vaccine effectiveness. The first platform uses the pyridoxal 5’-phosphate (PLP) synthase protein...

Published: 5/14/2026 | Updated: 3/23/2026 | Inventor(s): Niraj Tolia, Dashuang Shi, Vu Nguyen, Thayne Dickey

Keywords(s):

Category(s): TherapeuticArea, ResearchProducts, Collaboration Sought, Application > Vaccines

Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the clinical translation of novel peptide-based therapeutic cancer vaccines derived from ERVMER34-1, a human endogenous retrovirus (HERV) antigen, offering a unique opportunity to address a significant unmet need in the treatment of various carcinomas. Description...

Published: 9/29/2025 | Updated: 9/29/2025 | Inventor(s): Jeffrey Schlom, Duane Hamilton, Claudia Palena, Renee Donahue

Keywords(s):

Category(s): TherapeuticArea > Immunology, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Vaccines

EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques

Enterovirus D68 (EV-D68) has been linked to the widespread outbreaks of respiratory illness and acute flaccid myelitis (AFM) in the United States and Europe in 2014, 2016, and 2018. Although EV-D68 is now the most frequently encountered enterovirus (41.1% of cases), with an estimated global prevalence of 4%, there are no specific, FDA-approved therapeutic...

Published: 7/2/2025 | Updated: 7/2/2025 | Inventor(s): Tracy Ruckwardt, Daniel Moss, Peter Krug, Masaru Kanekiyo

Keywords(s):

Category(s): Application, Application > Diagnostics, Application > Therapeutics, Application > Vaccines, Collaboration Sought, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts, ResearchProducts > Antibodies, TherapeuticArea, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease

A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics

BSR T7/5 cells represent a foundational advancement in virology, offering a robust platform for the recovery of RNA viruses via reverse genetics. Established over 20 years ago, these cells have proven instrumental in the recovery of a wide array of RNA viruses, particularly those belonging to the mononegavirales order. By enabling the insertion of antigenome...

Published: 8/13/2025 | Updated: 12/10/2024 | Inventor(s): Ursula Buchholz

Keywords(s):

Category(s): Application > Therapeutics, Application > Vaccines, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Research Equipment, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease

A Key Advancement for Human Norovirus Research and Reverse Genetics

The HEK293T/T7 cell line is a novel development in virology research, particularly for studying human noroviruses. This cell line expresses the T7 RNA polymerase, a key enzyme used in reverse genetics systems. Unlike existing technologies, the HEK293T/T7 cell line offers the unique advantage of being able to produce functional T7 RNA polymerase, which...

Published: 10/27/2025 | Updated: 12/10/2024 | Inventor(s): Carlos Sandoval-Jaime, Stanislav Sosnovtsev

Keywords(s):

Category(s): Application > Therapeutics, Application > Vaccines, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Human Cell Lines, TherapeuticArea > Infectious Disease, TherapeuticArea > Rare/Neglected Diseases

Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense

The technology focuses on the development of a tetravalent bispecific antibody effective against Bacillus anthracis, the bacterium responsible for anthrax. This antibody combines the specificities of two monoclonal antibodies (mAbs): one targeting anthrax protective antigen (PA) and the other targeting the bacterial capsule. The anti-PA mAb shows potent...

Published: 12/10/2024 | Updated: 12/10/2024 | Inventor(s): Zhao Chun Chen, Robert Purcell, Mahtab Moayeri, Stephen Leppla

Keywords(s):

Category(s): Application > Therapeutics, Application > Vaccines, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Antibodies, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease

Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies

This technology represents a significant advancement in the field of rabies prevention, focusing on the development of highly potent rabies-neutralizing monoclonal antibodies (mAbs) for use in postexposure prophylaxis (PEP). With two mAbs, F2 and G5a, displaying exceptional neutralizing titers of 1154 and 3462 International Units (IUs) per milligram,...

Published: 8/13/2025 | Updated: 12/10/2024 | Inventor(s): Zhaochun Chen, Robert Purcell, Joseph Blaney

Keywords(s):

Category(s): Application > Diagnostics, Application > Therapeutics, Application > Vaccines, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Antibodies, ResearchProducts > Research Equipment, TherapeuticArea > Infectious Disease

1 2 3 4 5 6 7 8 9 10 ...